These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 494629)

  • 41. Tests of fibrin metabolism in recurrent venous thromboembolism.
    Bynum LJ; Parkey RW; Wilson JE
    Arch Intern Med; 1977 Oct; 137(10):1385-9. PubMed ID: 921420
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Thromboembolic complications in the pulmonary vascular bed in patients with acute myocardial infarct].
    Donicowa K
    Kardiol Pol; 1977; 20(6):445-51. PubMed ID: 604609
    [No Abstract]   [Full Text] [Related]  

  • 43. Prototype quantitative assay for fibrinogen/fibrin degradation products. Clinical evaluation.
    Sigal SH; Cembrowski GS; Shattil SJ; Brown NM; Schifreen RS; Schwartz MW
    Arch Intern Med; 1987 Oct; 147(10):1790-3. PubMed ID: 3662708
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The use of a rapid D-dimer blood test in the diagnostic work-up for pulmonary embolism: a management study.
    de Groot MR; van Marwijk Kooy M; Pouwels JG; Engelage AH; Kuipers BF; Büller HR
    Thromb Haemost; 1999 Dec; 82(6):1588-92. PubMed ID: 10613639
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Increased plasma levels of fibrinogen in acute and chronic ischemic coronary syndromes.
    Abrignani MG; Novo G; Di Girolamo A; Caruso R; Tantillo R; Braschi A; Braschi GB; Strano A; Novo S
    Cardiologia; 1999 Dec; 44(12):1047-52. PubMed ID: 10687254
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Determination of fibrinogen/fibrin degradation products for diagnostic purposes in internal diseases].
    Iwańska J; Donicowa K; Barańska H; Jarczewski J
    Pol Tyg Lek; 1977 Jun; 32(26):993-6. PubMed ID: 882451
    [No Abstract]   [Full Text] [Related]  

  • 47. Relationship between fibrinopeptide A and fibrinogen/fibrin fragment E in thromboembolism, DIC and various non-thromboembolic diseases.
    Mombelli G; Monotti R; Haeberli A; Straub PW
    Thromb Haemost; 1987 Aug; 58(2):758-63. PubMed ID: 3672428
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Serial changes in hemostatic molecular markers after urokinase therapy of acute myocardial infarction].
    Goto S; Kawai Y; Watanabe K; Hori S; Abe S; Handa S; Ikeda Y
    Kokyu To Junkan; 1992 Jan; 40(1):89-95. PubMed ID: 1532665
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Fibrinogen and fibrin degradation products in serum and their prognostic significance in acute myocardial infarct].
    Krug H; Gryglik J; Jasiński K; Gluszek J
    Kardiol Pol; 1977; 20(1):9-14. PubMed ID: 846061
    [No Abstract]   [Full Text] [Related]  

  • 50. Sustained fibrinolysis after administration of t-PA despite its short half-life in the circulation.
    Eisenberg PR; Sherman LA; Tiefenbrunn AJ; Ludbrook PA; Sobel BE; Jaffe AS
    Thromb Haemost; 1987 Feb; 57(1):35-40. PubMed ID: 3109058
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunoenzyme histochemical localization of fibrin degradation products in tissues.
    Emeis JJ; Lindeman J; Nieuwenhuizen W
    Am J Pathol; 1981 Jun; 103(3):337-44. PubMed ID: 7015871
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical utility of serum fibrinogen degradation products (FDP) in the diagnostic and prognostic evaluation of oral cancer.
    Ghosh M; Aroor AR; Raghavan MR
    Ann Dent; 1990; 49(2):11-2, 45. PubMed ID: 2278474
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Determination of plasma fibrinogen and fibrin degradation products (FDP) in 100 normal persons and 32 cases of acute cerebrovascular disease (author's transl)].
    Wang GX
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1982 Feb; 15(1):8-10. PubMed ID: 7094732
    [No Abstract]   [Full Text] [Related]  

  • 54. [Possibilities of using immunoenzyme test systems for determining levels of myoglobin, fibrinogen, fibrin-fibrinogen degradation products and fibronectin in the diagnosis of somatic diseases].
    Ermolin GA; Shelepova TM; Dikov MM; Osmanov SK; Voloshchuk OM
    Biull Vsesoiuznogo Kardiol Nauchn Tsentra AMN SSSR; 1987; 10(1):33-7. PubMed ID: 3300700
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Application of a novel and rapid whole blood assay for D-dimer in patients with clinically suspected pulmonary embolism.
    Ginsberg JS; Wells PS; Brill-Edwards P; Donovan D; Panju A; van Beek EJ; Patel A
    Thromb Haemost; 1995 Jan; 73(1):35-8. PubMed ID: 7740493
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dynamic coronary fibrinolysis evaluation in patients with myocardial infarction and unstable angina by specific plasma fibrin degradation product determination.
    Soria C; Soria J; Mirshahi M; Mirshahi M; Dunnica S; Boucheix C; Beaufils R; Slama R; Caen JP
    Thromb Res; 1987 Feb; 45(4):383-92. PubMed ID: 3576522
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Thyroid hormones, cholesterol, erythrocyte aggregation and fibrinogen degradation products in acute myocardial infarct].
    Marek H; Titlbach O; Kellner K; Liusov VA; Rudakov AV
    Kardiologiia; 1980 Jan; 20(1):33-6. PubMed ID: 7354591
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fibrinogen degradation products in acute myocardial infarction.
    Buch J
    Dan Med Bull; 1979 Jul; 26(4):206-8. PubMed ID: 487868
    [No Abstract]   [Full Text] [Related]  

  • 59. [Fibrin degradation products].
    Baele G
    Acta Clin Belg; 1977; 32(6):386-90. PubMed ID: 616749
    [No Abstract]   [Full Text] [Related]  

  • 60. The transfer test: a new screening procedure for thrombotic diseases.
    Rodzynek JJ; Leautaud P; Martin T; Schoenfeld P; Wettendorff P; Delcourt A
    J Surg Res; 1983 Sep; 35(3):227-33. PubMed ID: 6887843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.